MA51155A - Compositions comprenant des polyribonucléotides circulaires et leurs utilisations - Google Patents
Compositions comprenant des polyribonucléotides circulaires et leurs utilisationsInfo
- Publication number
- MA51155A MA51155A MA051155A MA51155A MA51155A MA 51155 A MA51155 A MA 51155A MA 051155 A MA051155 A MA 051155A MA 51155 A MA51155 A MA 51155A MA 51155 A MA51155 A MA 51155A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions consisting
- circular polyribonucleotides
- polyribonucleotides
- circular
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762599547P | 2017-12-15 | 2017-12-15 | |
| US201862676688P | 2018-05-25 | 2018-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51155A true MA51155A (fr) | 2020-10-21 |
Family
ID=66820668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051155A MA51155A (fr) | 2017-12-15 | 2018-12-14 | Compositions comprenant des polyribonucléotides circulaires et leurs utilisations |
Country Status (13)
| Country | Link |
|---|---|
| US (12) | US12357653B2 (fr) |
| EP (1) | EP3724208A4 (fr) |
| JP (3) | JP2021508490A (fr) |
| KR (2) | KR20260109980A (fr) |
| CN (3) | CN120774994A (fr) |
| AU (2) | AU2018385757B2 (fr) |
| BR (1) | BR112020011670A2 (fr) |
| CA (1) | CA3084824A1 (fr) |
| IL (2) | IL275205B2 (fr) |
| MA (1) | MA51155A (fr) |
| MX (1) | MX2020006150A (fr) |
| SG (1) | SG11202005060YA (fr) |
| WO (1) | WO2019118919A1 (fr) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020006150A (es) | 2017-12-15 | 2020-11-11 | Flagship Pioneering Innovations Vi Llc | Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas. |
| CN112399860B (zh) | 2018-06-06 | 2024-08-16 | 麻省理工学院 | 用于在真核细胞中翻译的环状rna |
| CN121081491A (zh) | 2019-03-04 | 2025-12-09 | 旗舰创业创新第六有限责任公司 | 环状多核糖核苷酸及其药物组合物 |
| CN115806976A (zh) * | 2019-03-20 | 2023-03-17 | 中国科学院上海营养与健康研究所 | 利用环形rna进行蛋白翻译及其应用 |
| CN114207134B (zh) * | 2019-03-25 | 2024-11-15 | 俄亥俄州国家创新基金会 | 工程化的mRNA序列及其用途 |
| JP7618577B2 (ja) | 2019-03-25 | 2025-01-21 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 修飾環状ポリリボヌクレオチドを含む組成物及びその使用 |
| JP7686574B2 (ja) | 2019-05-22 | 2025-06-02 | マサチューセッツ インスティテュート オブ テクノロジー | 環状ｒｎａ組成物及び方法 |
| US20220257794A1 (en) * | 2019-06-14 | 2022-08-18 | Flagship Pioneering Innovations Vi, Llc | Circular rnas for cellular therapy |
| US12636369B2 (en) | 2019-06-19 | 2026-05-26 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof |
| AU2020296190A1 (en) | 2019-06-19 | 2022-01-06 | Flagship Pioneering Innovations Vi, Llc | Methods of dosing circular polyribonucleotides |
| CN112662659B (zh) * | 2019-10-15 | 2022-08-19 | 武汉核圣生物技术有限公司 | 一种普适性的mRNA体外环化方法 |
| WO2021081261A1 (fr) * | 2019-10-22 | 2021-04-29 | The Regents Of The University Of California | Modulation de la traduction des récepteurs des cellules immunitaires modifiées à l'aide d'éléments de séquence non codants |
| CA3159799A1 (fr) * | 2019-12-02 | 2021-06-10 | Prashant MALI | Ingenierie d'arn guides circulaires |
| MX2022006854A (es) | 2019-12-04 | 2022-11-30 | Orna Therapeutics Inc | Composiciones y metodos de arn circular. |
| EP4096681A1 (fr) | 2020-01-29 | 2022-12-07 | Flagship Pioneering Innovations VI, LLC | Administration de compositions comprenant des polyribonucléotides circulaires |
| TW202142689A (zh) | 2020-01-29 | 2021-11-16 | 美商旗艦先鋒創新有限責任公司 | 用於轉譯之組合物及其使用方法 |
| US20240245805A1 (en) * | 2020-03-20 | 2024-07-25 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| CN116322788A (zh) * | 2020-05-19 | 2023-06-23 | 奥纳治疗公司 | 环状rna组合物和方法 |
| IL298363A (en) | 2020-05-20 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and uses thereof |
| WO2021236952A1 (fr) | 2020-05-20 | 2021-11-25 | Flagship Pioneering, Inc. | Compositions et procédés de production d'anticorps polyclonaux humains |
| AU2021275223A1 (en) * | 2020-05-20 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc. | Coronavirus antigen compositions and their uses |
| CN111733243A (zh) * | 2020-06-29 | 2020-10-02 | 中山大学孙逸仙纪念医院 | 一种提高CircRNA检测准确率的方法 |
| CN116194581A (zh) * | 2020-07-01 | 2023-05-30 | 艾勒维生技公司 | 使用环状rna进行细胞重编程的组合物和方法 |
| JP2023539454A (ja) | 2020-08-12 | 2023-09-14 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム |
| IL300947A (en) | 2020-09-03 | 2023-04-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and uses thereof |
| CA3206361A1 (fr) | 2020-12-23 | 2022-06-30 | Flagship Pioneering Innovations V, Inc. | Assemblage in vitro de capsides d'anellovirus renfermant de l'arn |
| CN112562788B (zh) * | 2020-12-28 | 2022-06-28 | 上海交通大学 | 一种环状rna-rna结合蛋白关系预测模型构建方法 |
| AU2022234607B2 (en) | 2021-03-10 | 2025-01-23 | Rznomics Inc. | Self-circularized RNA structure |
| TW202300650A (zh) | 2021-03-26 | 2023-01-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 真核系統中環狀多核糖核苷酸的產生 |
| US20250188505A1 (en) | 2021-03-26 | 2025-06-12 | Flagship Pioneering Innovations Vii, Llc | Production of circular polyribonucleotides in a prokaryotic system |
| AR125216A1 (es) | 2021-03-26 | 2023-06-28 | Flagship Pioneering Innovations Vii Llc | Producción de polirribonucleótidos circulares en un sistema eucariota |
| EP4313109A1 (fr) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer |
| EP4341423A1 (fr) | 2021-05-18 | 2024-03-27 | Flagship Pioneering Innovations VI, LLC | Procédés d'enrichissement de polyribonucléotides circulaires |
| JP2024521304A (ja) | 2021-05-18 | 2024-05-31 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 環状ポリリボヌクレオチドを濃縮する方法 |
| US20230046606A1 (en) | 2021-07-15 | 2023-02-16 | Turn Biotechnologies, Inc. | Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use |
| US20230044997A1 (en) | 2021-07-15 | 2023-02-09 | Turn Biotechnologies, Inc. | Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment |
| KR20240047986A (ko) | 2021-07-27 | 2024-04-12 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 가공을 위한 디바이스, 시스템 및 방법 |
| AU2022332372B2 (en) | 2021-08-27 | 2025-12-04 | Peking University | Constructs and methods for preparing circular rna |
| WO2023044343A1 (fr) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Lipides acycliques et leurs procédés d'utilisation |
| TW202328067A (zh) | 2021-09-14 | 2023-07-16 | 美商雷納嘉德醫療管理公司 | 環狀脂質及其使用方法 |
| AR127073A1 (es) | 2021-09-17 | 2023-12-13 | Flagship Pioneering Innovations Vi Llc | Composiciones y métodos para producir polirribonucleótidos circulares |
| EP4419706A1 (fr) | 2021-10-18 | 2024-08-28 | Flagship Pioneering Innovations VI, LLC | Compositions et procédés de purification de polyribonucléotides |
| EP4422698A1 (fr) * | 2021-10-29 | 2024-09-04 | CureVac SE | Arn circulaire amélioré pour exprimer des protéines thérapeutiques |
| WO2023086796A2 (fr) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Bactéries immunostimulatrices pour convertir des macrophages en un phénotype pouvant être traité, et diagnostic compagnon pour identifier des sujets pour un traitement |
| IL312965A (en) * | 2021-11-24 | 2024-07-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and their uses |
| MX2024006407A (es) | 2021-11-24 | 2024-08-19 | Flagship Pioneering Innovations Vi Llc | Composiciones de inmunogenos del virus varicela-zoster y sus usos. |
| WO2023096990A1 (fr) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovation Vi, Llc | Compositions immunogènes de coronavirus et leurs utilisations |
| KR102488280B1 (ko) * | 2021-11-25 | 2023-01-16 | 주식회사 뉴클릭스바이오 | 신규한 부목 dna 및 이의 용도 |
| CN118510896A (zh) | 2021-12-17 | 2024-08-16 | 旗舰创业创新六公司 | 用于在变性条件下富集环状rna的方法 |
| EP4453201A1 (fr) | 2021-12-22 | 2024-10-30 | Flagship Pioneering Innovations VI, LLC | Compositions et procédés de purification de polyribonucléotides |
| WO2023122752A1 (fr) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Lipides contraints et procédés d'utilisation associés |
| AU2022420620A1 (en) | 2021-12-23 | 2024-07-04 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| CN118451182A (zh) * | 2022-01-28 | 2024-08-06 | 北京昌平实验室 | 环状rna疫苗及其使用方法 |
| CA3255619A1 (fr) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Lipides cycliques et nanoparticules lipidiques (npl) pour l'apport d'acides nucléiques ou de peptides destinés à être utilisés dans la vaccination contre des agents infectieux |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| US20240042021A1 (en) | 2022-08-01 | 2024-02-08 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
| JP2025530198A (ja) | 2022-09-06 | 2025-09-11 | アルジノミクス インコーポレイティド | 自己環状化ｒｎａ構造体 |
| KR102881597B1 (ko) | 2022-09-06 | 2025-11-07 | 알지노믹스 주식회사 | 자가 환형화 rna 구조체 |
| WO2024077191A1 (fr) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer |
| EP4612296A1 (fr) | 2022-10-31 | 2025-09-10 | Flagship Pioneering Innovations VI, LLC | Compositions et procédés de purification de polyribonucléotides |
| WO2024102799A1 (fr) | 2022-11-08 | 2024-05-16 | Flagship Pioneering Innovations Vi, Llc | Compositions et procédés de production de polyribonucléotides circulaires |
| TW202430636A (zh) * | 2022-11-08 | 2024-08-01 | 財團法人國家衛生研究院 | 環狀ｒｎａ及其製備方法和應用 |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| KR102584714B1 (ko) | 2022-12-28 | 2023-10-10 | 라이보텍(주) | 덤벨 구조를 이용한 원형 rna 제조 방법 |
| EP4648794A2 (fr) | 2023-01-09 | 2025-11-19 | Flagship Pioneering Innovations VII, LLC | Vaccins et procédés associés |
| WO2024151687A1 (fr) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Commutateurs génétiques et leur utilisation dans le traitement du cancer |
| US20240252520A1 (en) | 2023-01-09 | 2024-08-01 | Beth Israel Deaconess Medical Center, Inc. | Therapeutic agents and their use for treating chronic wounds |
| US20240238473A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
| KR102581491B1 (ko) * | 2023-01-20 | 2023-09-25 | 한국과학기술원 | mRNA의 세포내 안정성과 생합성을 향상시키는 래리엇 캡 구조의 RNA, 및 이의 용도 |
| EP4654953A1 (fr) * | 2023-01-27 | 2025-12-03 | The Methodist Hospital | Procédés de fabrication et d'isolement d'arn circulaires et de compositions d'arn circulaire |
| JP2026503676A (ja) | 2023-01-27 | 2026-01-29 | セイル バイオメディシンズ インコーポレイテッド | 修飾脂質組成物およびその使用 |
| TW202438515A (zh) | 2023-02-06 | 2024-10-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫調節組合物及相關方法 |
| WO2024192291A1 (fr) | 2023-03-15 | 2024-09-19 | Renagade Therapeutics Management Inc. | Administration de systèmes d'édition de gènes et leurs procédés d'utilisation |
| EP4680276A1 (fr) | 2023-03-15 | 2026-01-21 | Flagship Pioneering Innovations VI, LLC | Compositions immunogènes et leurs utilisations |
| EP4680750A1 (fr) | 2023-03-15 | 2026-01-21 | Flagship Pioneering Innovations VI, LLC | Compositions comprenant des polyribonucléotides et leurs utilisations |
| EP4680595A2 (fr) | 2023-03-15 | 2026-01-21 | Renagade Therapeutics Management Inc. | Nanoparticules lipidiques comprenant des molécules d'arn codant destinées à être utilisées dans l'édition génique et en tant que vaccins et agents thérapeutiques |
| EP4698150A1 (fr) | 2023-04-19 | 2026-02-25 | Sail Biomedicines, Inc. | Administration de polynucléotides à partir de nanoparticules lipidiques comprenant de l'arn et des lipides ionisables |
| WO2024220752A2 (fr) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Compositions thérapeutiques à arn |
| WO2024220712A2 (fr) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Compositions vaccinales |
| EP4722368A1 (fr) * | 2023-05-26 | 2026-04-08 | Samsung Biologics Co., Ltd. | Nouvelle construction d'acide nucléique contenant une queue poly(a) présentant une structure secondaire ou tertiaire et son utilisation |
| WO2025006684A1 (fr) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Polyribonucléotides circulaires codant pour des polypeptides antifusogènes |
| WO2025042786A1 (fr) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprenant des polyribonucléotides circulaires et leurs utilisations |
| EP4771154A2 (fr) | 2023-09-01 | 2026-07-08 | Renagade Therapeutics Management Inc. | Systèmes et compositions d'édition génique, et méthodes de traitement du syndrome vexas |
| WO2025081042A1 (fr) | 2023-10-12 | 2025-04-17 | Renagade Therapeutics Management Inc. | Système d'édition de précision basé sur un modèle de nickase-rétron et méthodes d'utilisation |
| WO2025106915A1 (fr) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Polyribonucléotides circulaires codant le peptide 1 de type glucagon (glp-1) et leurs utilisations |
| WO2025106930A1 (fr) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Polyribonucléotides circulaires codant le peptide 2 de type glucagon (glp-2) et leurs utilisations |
| WO2025128871A2 (fr) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Nanoparticules lipidiques comprenant des molécules d'arn codant destinées à être utilisées dans l'édition de gènes et en tant que vaccins et agents thérapeutiques |
| WO2025135995A1 (fr) | 2023-12-18 | 2025-06-26 | 주식회사 뉴클릭스바이오 | Nouveau procédé de synthèse d'arn circulaire par utilisation de l'arn ligase |
| WO2025147583A1 (fr) | 2024-01-05 | 2025-07-10 | Sail Biomedicines, Inc. | Ligands pd-1 modifiés |
| WO2025155753A2 (fr) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Système, guides et procédés d'édition de gènes améliorés |
| US20250375499A1 (en) | 2024-01-26 | 2025-12-11 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025174765A1 (fr) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Nanoparticules lipidiques comprenant des molécules d'arn codant destinées à être utilisées dans l'édition génique et comme vaccins et agents thérapeutiques |
| CN120505342A (zh) * | 2024-02-18 | 2025-08-19 | 中山大学孙逸仙纪念医院 | 一种环状多倍串联rna正义链 |
| WO2025179198A1 (fr) | 2024-02-23 | 2025-08-28 | Sail Biomedicines, Inc. | Polyribonucléotides circulaires et arn linéaires non modifiés à immunogénicité réduite |
| CN118374525B (zh) * | 2024-04-22 | 2025-02-25 | 广州派真生物技术有限公司 | 一种环状rna转录载体及其制备方法和应用 |
| TW202613158A (zh) | 2024-05-16 | 2026-04-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫受體抑制蛋白及相關方法 |
| WO2025245111A1 (fr) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Protéines de ciblage d'immunorécepteurs et procédés associés |
| WO2026006593A1 (fr) | 2024-06-28 | 2026-01-02 | Orna Therapeutics, Inc. | Sites d'entrée interne des ribosomes synthétiques |
| WO2026096919A1 (fr) | 2024-11-01 | 2026-05-07 | Sail Biomedicines, Inc. | Nouveaux lipides à cœur dipeptidique, vecteurs lipidiques et méthodes d'utilisation de ceux-ci |
| WO2026122747A2 (fr) | 2024-12-05 | 2026-06-11 | Flagship Pioneering Innovations Vii, Llc | Nouvelles protéines immunomodulatrices et méthodes associées |
| WO2026148005A1 (fr) | 2025-01-03 | 2026-07-09 | Sail Biomedicines, Inc. | Compositions et procédés de purification de polyribonucléotides |
| WO2026152164A1 (fr) | 2025-01-13 | 2026-07-16 | Sail Biomedicines, Inc. | Nanoparticules lipidiques ciblant cd5 encapsulant des polyribonucléotides codant pour des récepteurs antigéniques chimériques, et méthodes de génération in vivo de lymphocytes t exprimant un récepteur antigénique chimérique |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU649066B2 (en) | 1990-07-25 | 1994-05-12 | Syngene, Inc. | Circular extension for generating multiple nucleic acid complements |
| US5426180A (en) | 1991-03-27 | 1995-06-20 | Research Corporation Technologies, Inc. | Methods of making single-stranded circular oligonucleotides |
| US5877160A (en) | 1991-05-31 | 1999-03-02 | Genta Incorporated | Compositions and methods of treatment of androgen-associated baldness using antisense oligomers |
| EP0604552B1 (fr) | 1991-09-18 | 1997-02-12 | Affymax Technologies N.V. | Procede de synthese de diverses collections d'oligomeres |
| US5639603A (en) | 1991-09-18 | 1997-06-17 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
| AU683011B2 (en) | 1992-01-13 | 1997-10-30 | Duke University | Enzymatic RNA molecules |
| US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
| DE59309571D1 (de) | 1992-08-04 | 1999-06-17 | Thomson Brandt Gmbh | Hochspannungs-Zeilentransformator für einen Fernsehempfänger |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| US5721099A (en) | 1992-10-01 | 1998-02-24 | Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
| US5565324A (en) | 1992-10-01 | 1996-10-15 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
| US5773244A (en) | 1993-05-19 | 1998-06-30 | Regents Of The University Of California | Methods of making circular RNA |
| US5440016A (en) | 1993-06-18 | 1995-08-08 | Torrey Pines Institute For Molecular Studies | Peptides of the formula (KFmoc) ZZZ and their uses |
| US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
| US5688997A (en) | 1994-05-06 | 1997-11-18 | Pharmacopeia, Inc. | Process for preparing intermediates for a combinatorial dihydrobenzopyran library |
| US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
| US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
| US5463564A (en) | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
| US5688696A (en) | 1994-12-12 | 1997-11-18 | Selectide Corporation | Combinatorial libraries having a predetermined frequency of each species of test compound |
| CA2225313A1 (fr) | 1995-06-21 | 1997-01-09 | Martek Biosciences Corporation | Banques combinatoires de composes biochimiques marques et procedes de production de telles banques |
| US5766903A (en) | 1995-08-23 | 1998-06-16 | University Technology Corporation | Circular RNA and uses thereof |
| CA2158237A1 (fr) | 1995-09-13 | 1997-03-14 | Paolo Favaretto | Siege avec dossier pivotant |
| US5731423A (en) | 1996-03-21 | 1998-03-24 | Transcell Technologies, Inc. | Process for preparing sulfoxides |
| US6429301B1 (en) | 1998-04-17 | 2002-08-06 | Whitehead Institute For Biomedical Research | Use of a ribozyme to join nucleic acids and peptides |
| US6210931B1 (en) | 1998-11-30 | 2001-04-03 | The United States Of America As Represented By The Secretary Of Agriculture | Ribozyme-mediated synthesis of circular RNA |
| AUPR604101A0 (en) | 2001-06-29 | 2001-07-26 | Unisearch Limited | Aptamers |
| DE10132780A1 (de) | 2001-07-06 | 2003-01-16 | Icon Genetics Ag | Plastidäre Genexpression über autonom replizierende Vektoren |
| EP2428570B1 (fr) | 2001-09-28 | 2018-05-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Molécules de micro arn |
| WO2005013901A2 (fr) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants |
| WO2005030983A2 (fr) | 2003-09-26 | 2005-04-07 | Circleamp, Inc. | Amplification de polynucleotides par amplification par cercle roulant |
| CA2559955C (fr) | 2004-03-15 | 2016-02-16 | City Of Hope | Procedes et compositions pour l'inhibition specifique de l'expression genetique par l'arn double brin |
| DE102004025881A1 (de) | 2004-05-19 | 2006-01-05 | Beiersdorf Ag | Oligoribonukleotide zur Beeinflussung des Haarwachstums |
| DE102005001784A1 (de) | 2005-01-13 | 2006-10-05 | Beiersdorf Ag | Oligoribonukleotide zur Reduktion der Schweißbildung durch RNA-Interferenz |
| FR2885808B1 (fr) | 2005-05-19 | 2007-07-06 | Oreal | Vectorisation de dsrna par des particules cationiques et utilisation topique. |
| WO2007145612A1 (fr) * | 2005-06-06 | 2007-12-21 | 454 Life Sciences Corporation | Séquençage d'extrémités appariées |
| US20100003753A1 (en) | 2005-08-01 | 2010-01-07 | Purdue Research Foundation | Multivalent rna nanoparticles for delivery of active agents to a cell |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| JP5296328B2 (ja) | 2007-05-09 | 2013-09-25 | 独立行政法人理化学研究所 | １本鎖環状ｒｎａおよびその製造方法 |
| KR20110110776A (ko) | 2008-12-18 | 2011-10-07 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| WO2010084371A1 (fr) | 2009-01-26 | 2010-07-29 | Mitoprod | Nouvelles molécules d'arn interférent circulaire |
| WO2010093788A2 (fr) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Molécules d'arn interférence substrats de dicer multiplexes ayant des séquences de jonction |
| KR101938548B1 (ko) | 2011-06-23 | 2019-01-15 | (주)아모레퍼시픽 | 마이크로 ｒｎａ를 포함하는 색소형성유전자 발현조절용 조성물 |
| WO2013053481A1 (fr) | 2011-10-11 | 2013-04-18 | Secutech International Pte. Ltd. | Diméthylsulfoxyde utilisé comme solvant pour des acides nucléiques |
| WO2013113326A1 (fr) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Composition pharmaceutique comprenant un complexe support polymère - charge et au moins un antigène de protéine ou de peptide |
| JP6284181B2 (ja) * | 2012-02-09 | 2018-02-28 | 国立研究開発法人理化学研究所 | 環状ｒｎａ及びタンパク質の製造方法 |
| WO2013151664A1 (fr) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Polynucléotides modifiés pour la production de protéines |
| CN104411338A (zh) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| AU2013312838B2 (en) | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| US20150299702A1 (en) | 2012-11-30 | 2015-10-22 | Aarhus Universitet | Circular rna for inhibition of microrna |
| WO2014164253A1 (fr) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Régions non traduites hétérologues pour arnm |
| DE102013005361A1 (de) | 2013-03-28 | 2014-10-02 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Polyribonucleotid |
| ES2746803T3 (es) | 2013-05-15 | 2020-03-06 | Robert Kruse | Traducción intracelular de ARN circular |
| CA2921556A1 (fr) | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Compositions et procedes pour la modulation d'arn |
| WO2015034925A1 (fr) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Polynucléotides circulaires |
| US20160243221A1 (en) * | 2013-10-18 | 2016-08-25 | Moderna Therapeutics, Inc. | Compositions and methods for tolerizing cellular systems |
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| AU2015289656A1 (en) * | 2014-07-16 | 2017-02-16 | Modernatx, Inc. | Circular polynucleotides |
| EP3054017A1 (fr) | 2015-02-03 | 2016-08-10 | Johann Wolfgang Goethe-Universität, Frankfurt am Main | ARN circulaire pour le diagnostic et traitement de maladies cardiovasculaires |
| EP3270881B1 (fr) | 2015-03-20 | 2018-12-26 | Unilever PLC, a company registered in England and Wales under company no. 41424 of | Compositions antiperspirantes |
| EP3303377B1 (fr) | 2015-06-05 | 2022-11-23 | Dana-Farber Cancer Institute, Inc. | Compositions et procédés pour thérapie génique transitoire à stabilité améliorée |
| CA2990883A1 (fr) | 2015-06-30 | 2017-01-05 | Ethris Gmbh | Polyribonucleotides codant pour une famille de cassettes de liaison a l'atp et formulations associees |
| AU2016317936A1 (en) * | 2015-09-04 | 2018-03-08 | Tocagen Inc. | Recombinant vectors comprising 2A peptide |
| CN105664239B (zh) | 2016-03-23 | 2018-08-07 | 成都交大麦迪克科技有限公司 | 一种自粘附皮肤修复水凝胶的制备方法 |
| WO2017222911A1 (fr) | 2016-06-20 | 2017-12-28 | The Board Of Trustees Of The Leland Stanford Junior University | Arn circulaires et leur utilisation dans l'immunomodulation |
| CN106222174B (zh) | 2016-08-12 | 2020-08-04 | 青岛大学 | circRNA CHIF核苷酸在治疗心脏疾病中的用途 |
| AU2018251187B2 (en) | 2017-04-14 | 2024-03-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for transient gene therapy with enhanced stability |
| US20200131498A1 (en) | 2017-06-14 | 2020-04-30 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
| WO2018237372A1 (fr) | 2017-06-23 | 2018-12-27 | Cornell University | Molécules d'arn, procédés de production d'arn circulaire, et procédés de traitement |
| MX2020006150A (es) | 2017-12-15 | 2020-11-11 | Flagship Pioneering Innovations Vi Llc | Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas. |
| CN112399860B (zh) | 2018-06-06 | 2024-08-16 | 麻省理工学院 | 用于在真核细胞中翻译的环状rna |
| KR102950624B1 (ko) | 2018-07-24 | 2026-04-10 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 원형 폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도 |
| CN111603477B (zh) | 2019-02-25 | 2023-06-02 | 中国科学院分子细胞科学卓越创新中心 | 环形rna在系统性红斑狼疮制备治疗药物中的应用 |
| KR102901623B1 (ko) | 2019-03-01 | 2025-12-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 폴리리보뉴클레오티드 및 이의 미용적 용도 |
| MA55082A (fr) | 2019-03-01 | 2022-01-05 | Flagship Pioneering Innovations Vi Llc | Compositions, procédés, et kits pour l'administration de polyribonucléotides |
| CN121081491A (zh) | 2019-03-04 | 2025-12-09 | 旗舰创业创新第六有限责任公司 | 环状多核糖核苷酸及其药物组合物 |
| JP7618577B2 (ja) | 2019-03-25 | 2025-01-21 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 修飾環状ポリリボヌクレオチドを含む組成物及びその使用 |
| JP7686574B2 (ja) | 2019-05-22 | 2025-06-02 | マサチューセッツ インスティテュート オブ テクノロジー | 環状ｒｎａ組成物及び方法 |
| US20220257794A1 (en) | 2019-06-14 | 2022-08-18 | Flagship Pioneering Innovations Vi, Llc | Circular rnas for cellular therapy |
| US12636369B2 (en) | 2019-06-19 | 2026-05-26 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof |
| AU2020296190A1 (en) | 2019-06-19 | 2022-01-06 | Flagship Pioneering Innovations Vi, Llc | Methods of dosing circular polyribonucleotides |
| CN115279415A (zh) | 2020-01-29 | 2022-11-01 | 旗舰创业创新第六有限责任公司 | 用于蛋白调节的包含线性多核糖核苷酸的组合物及其用途 |
| EP4096681A1 (fr) | 2020-01-29 | 2022-12-07 | Flagship Pioneering Innovations VI, LLC | Administration de compositions comprenant des polyribonucléotides circulaires |
| TW202142689A (zh) | 2020-01-29 | 2021-11-16 | 美商旗艦先鋒創新有限責任公司 | 用於轉譯之組合物及其使用方法 |
| WO2021236952A1 (fr) | 2020-05-20 | 2021-11-25 | Flagship Pioneering, Inc. | Compositions et procédés de production d'anticorps polyclonaux humains |
| IL298363A (en) | 2020-05-20 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and uses thereof |
| AU2021275223A1 (en) | 2020-05-20 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc. | Coronavirus antigen compositions and their uses |
-
2018
- 2018-12-14 MX MX2020006150A patent/MX2020006150A/es unknown
- 2018-12-14 MA MA051155A patent/MA51155A/fr unknown
- 2018-12-14 KR KR1020267020634A patent/KR20260109980A/ko active Pending
- 2018-12-14 WO PCT/US2018/065836 patent/WO2019118919A1/fr not_active Ceased
- 2018-12-14 CN CN202510933666.0A patent/CN120774994A/zh active Pending
- 2018-12-14 KR KR1020207019809A patent/KR20200127152A/ko not_active Ceased
- 2018-12-14 EP EP18887999.3A patent/EP3724208A4/fr active Pending
- 2018-12-14 US US16/772,678 patent/US12357653B2/en active Active
- 2018-12-14 AU AU2018385757A patent/AU2018385757B2/en active Active
- 2018-12-14 CA CA3084824A patent/CA3084824A1/fr active Pending
- 2018-12-14 BR BR112020011670-0A patent/BR112020011670A2/pt unknown
- 2018-12-14 SG SG11202005060YA patent/SG11202005060YA/en unknown
- 2018-12-14 CN CN201880081133.2A patent/CN111819185A/zh active Pending
- 2018-12-14 IL IL275205A patent/IL275205B2/en unknown
- 2018-12-14 JP JP2020552672A patent/JP2021508490A/ja active Pending
- 2018-12-14 CN CN202510933687.2A patent/CN120737150A/zh active Pending
- 2018-12-14 IL IL316195A patent/IL316195A/en unknown
-
2019
- 2019-06-11 US US16/438,073 patent/US10953033B2/en active Active
-
2021
- 2021-02-11 US US17/173,991 patent/US11058706B2/en active Active
- 2021-05-06 US US17/313,963 patent/US11160822B2/en active Active
- 2021-09-22 US US17/482,346 patent/US11458156B2/en active Active
-
2022
- 2022-08-30 US US17/898,947 patent/US12539309B2/en active Active
- 2022-11-16 US US17/988,007 patent/US11844759B2/en active Active
-
2023
- 2023-07-04 JP JP2023109861A patent/JP2023126888A/ja active Pending
- 2023-12-18 US US18/543,966 patent/US20240122959A1/en not_active Abandoned
-
2024
- 2024-01-17 AU AU2024200298A patent/AU2024200298A1/en active Pending
-
2025
- 2025-06-16 US US19/239,068 patent/US20250381211A1/en active Pending
- 2025-10-27 JP JP2025181174A patent/JP2026016607A/ja active Pending
- 2025-12-22 US US19/429,999 patent/US20260124228A1/en active Pending
- 2025-12-22 US US19/430,009 patent/US20260124229A1/en active Pending
- 2025-12-22 US US19/430,026 patent/US20260115219A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3724208A4 (fr) | Compositions comprenant des polyribonucléotides circulaires et leurs utilisations | |
| EP3827084A4 (fr) | Compositions comprenant des polyribonucléotides circulaires et utilisations associées | |
| EP3419676A4 (fr) | Compositions antimicrobiennes et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| EP3328199A4 (fr) | Compositions antimicrobiennes et leurs utilisations | |
| EP3625263A4 (fr) | Anticorps anti-galectine-9 et leurs utilisations | |
| EP3600273A4 (fr) | Inhibiteurs de cd73 et leurs utilisations | |
| EP3471727A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3472129A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| MA45943A (fr) | Compositions ignifuges et leurs utilisations | |
| EP3370528A4 (fr) | Compositions probiotiques et leurs utilisations | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| EP3413816A4 (fr) | Compositions hydratantes et utilisations associées | |
| EP3283517A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3790861A4 (fr) | Compositions sénolytiques et utilisations associées | |
| EP3349802A4 (fr) | Dendrimères lipocationiques et leurs utilisations | |
| MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
| EP3583219A4 (fr) | Compositions probiotiques et utilisations correspondantes | |
| MA50465A (fr) | Compositions de peptides tau phosphorylés et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| EP3471726A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3655043A4 (fr) | Compositions topiques et leurs utilisations |